EARLY PREDICTIVE IMMUNOASSAY FOR PREECLAMPSIA

Information

  • Research Project
  • 3499822
  • ApplicationId
    3499822
  • Core Project Number
    R43HD027367
  • Full Project Number
    1R43HD027367-01A1
  • Serial Number
    27367
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/12/1991 - 33 years ago
  • Project End Date
    2/11/1992 - 32 years ago
  • Program Officer Name
  • Budget Start Date
    8/12/1991 - 33 years ago
  • Budget End Date
    2/11/1992 - 32 years ago
  • Fiscal Year
    1991
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/12/1991 - 33 years ago
Organizations

EARLY PREDICTIVE IMMUNOASSAY FOR PREECLAMPSIA

DESCRIPTION: (Adapted from the applicant's abstract) The investigators propose to develop a new diagnostic test to improve substantially the definitive diagnosis of PE. PE is a common disease of pregnant women affecting the mother, fetus, and neonate. PE is characterized by the onset of hypertension, proteinuria and edema after the 20th week of gestation in previously normotensive women. Recent studies suggest that the primary pathogenesis of this disorder is uteroplacental perfusion insufficiency resulting in general maternal vascular endothelial cell damage. Although PE complicates only 3-7 percent of pregnancies, it is responsible for about l2 percent of all perinatal deaths, largely due to complications associated with premature delivery. Although more than l00 clinical, biochemical and biophysical tests have been put forth as predictors of PE, there is as yet no reliable marker of the early detection of PE. In preliminary studies, the investigators have determined that endothelial cell ICAM-l is significantly elevated in women with PE compared to matched normal pregnancies. The overall objective of Phase I study will be to characterize the ICAM-l as diagnostic marker for PE. In Phase II study, they will design a prospective clinical trial to evaluate thoroughly the diagnostic efficacy and commercial potential of ICAM-l as a marker for PE.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R43
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    ADEZA BIOMEDICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SUNNYVALE
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94089
  • Organization District
    UNITED STATES